Mesoblast Reports Ryoncil Revenue for Q4 and Full Year
Key points
- Ryoncil Q4 net revenue: $36M
- Full-year net revenue: $115M
- Strong uptake since launch, exceeding initial projections
Full summary
Mesoblast Ltd. announced that its product Ryoncil achieved a net revenue of US$36 million for the fourth quarter and US$115 million for the full fiscal year ending June 30, 2026. The company expressed satisfaction with the strong uptake of Ryoncil since its launch and highlighted that the revenues have surpassed initial projections. Mesoblast's CEO, Dr. Silviu Itescu, anticipates continued revenue growth in the upcoming fiscal year, aligning with the momentum observed across major U.S. pediatric centers. The company's capital position is robust, and operational activities are well-funded through revenue growth. Additionally, the new five-year facility has enabled strategic initiatives for label extension and blockbuster products.
Guidance
Ryoncil Q4 net revenue: $36M, Full-year net revenue: $115M
Outlook
Mesoblast anticipates continued revenue growth in the upcoming fiscal year, aligning with the momentum observed across major U.S. pediatric centers.
Summary generated by a large language model. Please interpret with care.